Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
Exelixis presented positive subgroup data from the Phase 3 CABINET trial, showing cabozantinib significantly improved progression-free survival in both functional and non-functional neuroendocrine tumors. In non-functional NET, the hazard ratio was 0.26 (74% risk reduction) with a median PFS of 9.4 months versus 3.1 months for placebo. In functional NET, the hazard ratio was 0.40 (60% risk reduction) with a median PFS of 12.7 months versus 5.4 months for placebo.
Key figures
- Drug Name
- CABOMETYX (cabozantinib)
- Phase Of Trial
- Phase 3
- Pfs functional hr
- 0.4
- Pfs non functional hr
- 0.26
- Total patients enrolled
- 298
- Risk reduction functional
- 60%
- Pfs functional median months
- 12.7
- Pfs functional placebo months
- 5.4
- Risk reduction non functional
- 74%
- Pfs non functional median months
- 9.4
- Pfs non functional placebo months
- 3.1
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.